A Study of LM-24C5 For Advanced Solid Tumors
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
Advanced Solid Tumor
DRUG: LM-24C5
Incidence of adverse events (AEs), Phase 1, 60 weeks|Incidence of dose-limiting toxicity (DLT), Phase 1, 60 weeks|Incidence of serious adverse event (SAE), Phase 1, 60 weeks|Ear Temperature, Phase 1, 60 weeks|Pulse in BPM(Beat per Minute), Phase 1, 60 weeks|Blood Pressure in mmHg (Both Systolic and Diastolic blood pressure), Phase 1, 60 weeks|Number of participants with abnormal Hematology test results, Phase 1, 60 weeks|Number of participants with abnormal Urinalysis test results, Phase 1, 60 weeks|Number of participants with abnormal Blood Biochemistry test results, Phase 1, 60 weeks|Number of participants with abnormal Coagulation test results in PT(Prothrombin time), APTT(Activated partial thromboplastin time), FIB(Fibrinogen), TT(Thrombin time) and INR(International normalized ratio)., Phase 1, 60 weeks|Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage, Phase 1, 60 weeks|12-lead electrocardiogram (ECG) in RR, PR, QRS, QT, QTcF etc., Phase 1, 60 weeks|ECOG(Eastern Cooperative Oncology Group) score, Phase 1, 60 weeks|Overall Response Rate (ORR), Phase 2, 36 weeks
Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax), Phase 1 and 2, 96 weeks|PK Parameter:Time of Maximum Observed Concentration (Tmax), Phase 1 and 2, 96 weeks|PK Parameter: Area Under the Concentration-time Curve(AUC), Phase 1 and 2, 96 weeks|PK Parameter: Steady State Maximum Concentration(Cmax,ss), Phase 1 and 2, 96 weeks|PK Parameter: Steady State Minimum Concentration(Cmin,ss), Phase 1 and 2, 96 weeks|PK Parameter: Systemic Clearance at Steady State (CLss), Phase 1 and 2, 96 weeks|PK Parameter: Accumulation Ratio (Rac), Phase 1 and 2, 96 weeks|PK Parameter: Elimination Half-life (t1/2), Phase 1 and 2, 96 weeks|PK Parameter: Volume of Distribution at Steady-State (Vss), Phase 1 and 2, 96 weeks|PK Parameter: Degree of Fluctuation (DF), Phase 1 and 2, 96 weeks|Immunogenicity of LM-24C5, Phase 1 and 2; Anti-Drug antibody and Nab (if necessary) will be tested., 96 weeks|Duration of Response (DOR) in Month, Phase 1 and 2, 96 weeks|Disease control rate (DCR) in percentage, Phase 1 and 2, 96 weeks|progression-free survival (PFS) in Month, Phase 1 and 2, 96 weeks|Overall survival (OS) in Month, Phase 1, 60 weeks|Changes of target lesions from baseline in Millimeter., Phase 1 and 2, 96 weeks|Safety: AE/SAE (Number of participants with treatment-related adverse events as assessed by CTCAE v5.0), Phase 2, 36 weeks|Ear Temperature, Phase 2, 36 weeks|Pulse in BPM (Beat per Minute), Phase 2, 36 weeks|Blood Pressure in mmHg (Both Systolic and Diastolic blood pressure), Phase 2, 36 weeks|Number of participants with abnormal Hematology test results, Phase 2, 36 weeks|Number of participants with abnormal Urinalysis test results, Phase 2, 36 weeks|Number of participants with abnormal Blood Biochemistry test results, Phase 2, 36 weeks|Number of participants with abnormal Coagulation test results in PT(Prothrombin time), APTT(Activated partial thromboplastin time), FIB(Fibrinogen), TT(Thrombin time) and INR(International normalized ratio)., Phase 2, 36 weeks|12-lead electrocardiogram (ECG) in RR, PR, QRS, QT, QTcF etc., Phase 2, 36 weeks|ECOG(Eastern Cooperative Oncology Group) score, Phase 2, 36 weeks
Relationship between the biomarkers and the anti-tumor activity, Phase 1 and 2, 96 weeks
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.